18 Apr 2016 13:03
Hardman & Co issues research report on Premaitha Health plc
18.04.16 CORRECTION: PLEASE NOTE THAT THE LINK TO THE FULL RESEARCH REPORT HAS BEEN REPLACED. NO FURTHER CONTENT HAS BEEN AMENDED.
IONA™ - Up, running and available on the NHS: Premaitha uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests. IONA estimates the risk that a fetus has any of Down's, Edwards' or Patau's syndromes caused by a genetic abnormality. Although IONA is entering a competitive and litigious market, it has some advantages, is CE Marked and is the first to win a UK NHS contract. Premaitha is subject to distracting IP infringement claims but 1H'16 results showed early signs of commercial traction which are expected to accelerate herein. Also, Premaitha has signed a strategically important partnership with Thermo Fisher which adds considerable credibility.
Please click here for the full report:
http://www.hardmanandco.com/docs/default-source/company-docs/premaitha-health-plc-documents/nipt-initiation-note---28-jan-2016
To contact us: Hardman & Co 11/12 Tokenhouse Yard London EC2R 7AS | Contact: Dr Martin Hall mh@hardmanandco.com Telephone: +44 20 7929 3399 Follow us on Twitter @HardmanandCo
|
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.